In the IMFORTE phase III trial enrolling patients with advanced SCLC whose disease had not progressed after induction therapy, maintenance therapy with lurbinectedin plus atezolizumab (anti-PD-L1 antibody) significantly prolonged progression-free survival compared with atezolizumab alone.8 The gene discussed is CD274; the disease is small cell lung carcinoma.